ArticleJournal of neuro-oncology2026
Disparities in stereotactic radiosurgery receipt in patients with brain metastases from non-small cell lung cancer.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStereotactic radiosurgery (SRS) is a commonly used alternative to whole-brain radiotherapy for patients with a limited burden of brain metastases from non-small cell lung cancer (NSCLC), but SRS receipt may be influenced by various sociodemographic factors. We sought to describe disparities in SRS receipt among adult patients with brain metastasis from NSCLC in the US.
methodsWe used the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to characterize disparities in SRS receipt. Analysis focused on adults diagnosed with brain metastases at the time of NSCLC diagnosis. Our outcome was receipt of SRS versus non-SRS radiotherapy. We developed a hierarchical multivariable logistic regression model to identify predictors of SRS receipt.
resultsMedicare beneficiaries living in rural versus urban locations (odds ratio [OR] 0.80, 95% confidence interval [CI] 0.67-0.96, p = 0.019) and with ≥ 3 versus no comorbidities (OR 0.77, 95% CI 0.66-0.91, p = 0.007) had lower odds of SRS receipt. Patient sociodemographic factors, including race and ethnicity, were not associated with SRS receipt. Before the 2014 "Choosing Wisely" guidelines, dual Medicare/Medicaid eligibility was associated with lower odds of SRS receipt (OR 0.74, 95% CI 0.57-0.96, p = 0.021). In the years after the guidelines, odds of SRS receipt was lower among rural patients (OR 0.79, 95% CI 0.62-1.00, p = 0.045) and those with ≥ 3 comorbidities (OR 0.76, 95% CI 0.61-0.94, p = 0.036).
conclusionsNationally, we observed differences in SRS receipt in Medicare beneficiaries with a greater number of comorbidities and those living in rural areas. This data suggests that there may be subpopulations in need of targeted interventions to improve equitable SRS receipt.
Indexed as
Identifiers
42141140What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.